Group items tagged

Well Pharmacy has introduced a digital e-voucher platform for its corporate flu vaccination scheme. This platform simplifies the process of distributing flu vouchers to colleagues via email, employing individual flu voucher codes for each recipient, the company said in a statement. "Flu can disrupt business operations, especially during the bustling pre-Christmas period," said George Sandhu, Deputy Superintendent Pharmacist at Well Pharmacy. "Opting for staff flu jabs is a cost-effective means of safeguarding your business, employees, and their families. Our goal is to ensure a seamless setup, effortless administration, and convenient access to flu jabs for your colleagues, fitting into their schedules smoothly." According to the statement, Well Pharmacy's digital e-voucher platform offers effortless accessibility and various benefits, including swift email sharing, transparent upfront pricing and invoicing, and convenient tracking of voucher usage. Businesses can also track the utilisation and remaining availability of vouchers. "Just determine the desired number of vouchers and complete the order form," Sandhu added. "We'll provide a pre-filled agreement for your signature and return, along with an invoice. After setup, you'll receive a voucher code to distribute among your staff, along with promotional posters. They can access our website to obtain the necessary code for scheduling their vaccinations."

Pharmacy bodies are "bitterly disappointed" that the latest deal on the national contract makes no commitment to "fresh funding", with one organisation calling it "the biggest dis-service ever done" to community pharmacy. The only commitment made in monetary terms was one in which NHS England agreed to write off a sum of £100m in excess margin earned by contractors in previous years. This allowance, which can't be seen as new cash injection, was said to have been made in recognition of the pressures facing the sector. The figure - reached after what the the Pharmaceutical Services Negotiating Committee called "a tense period of negotiations" with the Department of Health and Social Care and NHS England - will cover the final two years of the current five-year Community Pharmacy Contractual Framework. The deal was announced by PSNC chief executive Janet Morrison at an annual LPC Conference in Manchester on Thursday (22 September). Welcoming the attendees, she assured everyone that the committee was well aware of the pressures the sector was facing. "I heard how contractors are feeling and their frustrations over growing pressure and lack of financial support from the government. They confirmed that many now are unable to deliver the full range of services, and others are struggling to maintain core levels of services. And the ongoing impact of capacity and workforce crisis is critical, leading to temporary closures.

Community pharmacists in England have launched a new digital platform called My Local Surgery, enabling patients to access Pharmacy First consultations online. This initiative, a part of the NHS Pharmacy First scheme, facilitates free video consultations for six common conditions, connecting patients with community pharmacists for clinical advice and treatment. The platform, spearheaded by a team of pharmacy, tech, and clinical services experts, including experienced community pharmacists Darren Lingaloo and Gulraj Dhillon, tech specialist Nav Ramiah, and Dr. Adam Kirk, a seasoned NHS and digital healthcare professional, seeks to meet the rising demand for clinical services. Darren Lingaloo, co-founder and chief pharmacist at My Local Surgery, said: "The evolving role of pharmacists is long overdue and has the potential to save millions of GP appointments every year.

The Association of the British Pharmaceutical Industry (ABPI) has proposed a Voluntary Scheme for Pricing, Access and Growth (VPAG) that aims to deliver a sustainable approach to medicines provision and maximise the growth potential of the UK life sciences industry. It has published the industry's vision for a new agreement with the government which will deliver for patients, the NHS and the economy. VPAG also includes measures to ensure rapid patient access and adoption of new medicines, as well as opportunities to improve health outcomes and productivity for the whole country. The association's proposals consist of four key areas: restoring an internationally competitive commercial environment for life sciences; supporting UK clinical research and R&D; ensuring rapid patient access and uptake of new medicines; and improving population health and productivity through health innovation. The proposal would deliver over £1bn a year to the NHS - around £300m more than the average delivered under the old scheme before 2023, and comfortably more than the highest contributions ever made before the pandemic.

Scottish community pharmacies will now hold two Naloxone kits, available in either nasal spray or injectable form, essential for reversing opioid overdoses. The Emergency Access Naloxone Scheme, which is backed by £300,000 of Scottish Government funding, began on Monday (30 October). Drugs and Alcohol Policy Minister Elena Whitham said, "Through our National Mission to reduce drug deaths and harms, we have invested more than £3 million in widening access to Naloxone, including through our emergency services." Witham said this new nationwide service is a welcome addition to existing services. "Police Scotland recently completed a force-wide rollout to 12,500 officers who have used the kits more than 300 times. According to the most recent statistics, 70 per cent of those who are at risk of opioid overdose are being provided with a lifesaving kit," she added. "It provides a substantial increase in life-saving emergency access and I'm grateful to all those in community pharmacies who are supporting our £250 million National Mission to reduce drug deaths," Whitham said.

The National Pharmacy Association (NPA) has emphasised that the community pharmacy sector must be involved right from the start in all local planning meetings pertaining to the roll-out of vaccine services in potential future pandemics. This includes crucial discussions regarding supply logistics and resource allocation, lawyers representing the NPA told COVID-19 public inquiry hearing. Chaired by Baroness Heather Hallett, the independent public inquiry is examining the UK's response to the Covid-19 pandemic and lessons for the future. The NPA has been designated as a 'core participant' in Module 4 (vaccines) of the inquiry, which considers various issues related to vaccine development and rollout, as well as Module 3 (healthcare). During the hearing on September 13, NPA lawyers outlined three key areas the association says must be improved in future pandemic vaccination programs, including properly utilising existing primary care expertise, better planning and engagement, and improved access to information for community pharmacists.

Community pharmacies in England will continue to receive the free protective equipment (PPE) as the Government's scheme has been extended for another year until March 2024. The Department of Health and Social Care (DHSC) has announced that it will continue to supply all categories of PPE, free of charge, for frontline health and social care staff according to demand until the end of March 2024, or when stocks run out. Last year, DHSC implemented a new and improved portal platform for eligible providers to access free COVID-19 related PPE supplies. The Pharmaceutical Services Negotiating Commitee (PSNC) said: "Community pharmacy teams can continue to order PPE from the NHS PPE portal for free for as long as stock is available."

The new Hormone Replacement Therapy (HRT) prescription pre-payment certificate (PPC) has witnessed more than 37,000 purchases both via online website and in-person in pharmacies since its launch on Saturday (1 April). As of 12pm today (4 April), 37,240 HRT PPCs have been bought online and 501 in-pharmacy, totalling 37,741 certificates. Department of Health and Social Care (DHSC) estimated women have saved over £1.13 million in prescription charges for the year, with the average person saving £30 for a year's supply. The new prescription pre-payment certificate is also predicted to enable around 400,000 women to have cheaper access to menopause support. On the launch of the scheme on Saturday, the huge demand for the much-anticipated certificate meant some patients were unable to access the website on the morning of 1 April. "The NHS Business Service Authority has ensured that the site has been working, allowing thousands of women to continue to successfully purchase a prescription for a year's worth of hormone replacement therapy products which help treat the menopause," said DHSC. Minister for Women's Health Strategy, Maria Caulfield said: "Over 37,700 women have come forward to claim cheaper HRT this weekend alone, showing what happens when we listen to what women want.

The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June). The paper details how a financially sustainable VPAS can support widened medicines access to patients. VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. "The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme, data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the association.

The British Generic Manufacturers Association has backed the UK government's proposed changes to the Statutory Scheme for branded medicines, which includes a 'Life Cycle Adjustment' (LCA) mechanism to permit a lower rebate rate for medicines sold in competitive markets. The association underscored the necessity for crucial amendments to forestall unintended consequences and ensure a practical alignment with market operations. A precisely tailored approach is crucial in ensuring sustainability and growth in this sector, the BGMA said in a statement on Oct. 11. The Department of Health and Social Care is currently working on the successor to the 2019 voluntary scheme for branded medicines and pricing access (VPAS) agreement, slated to end in 2023. Negotiations for this successor, scheduled to begin on January 1, 2024, are already underway. "We are pleased that the Statutory Scheme consultation recognises that branded generic and biosimilar medicines are subject to different market dynamics and competitive pressures," said Mark Samuels, Chief Executive of BGMA. "As such, a one-size-fits-all approach across all branded products is not suitable for the next five years. It is crucial to adopt a precisely tailored approach to this sector, ensuring both sustainability and growth."

The NHS is on track to miss out on savings of over a billion pounds as patents for a new lineup of 85 biologics are set to expire within the next five years, the British Generic Manufacturers Association has revealed in its new study. The government's Voluntary Scheme for Branded Medicines Pricing and Access is expected to lead to a cost of more than £1 billion for the NHS in the coming years. The BGMA research found that more than 85 biological medicines will experience loss of exclusivity during the upcoming VPAS Scheme period from 2024 to 2028. "This includes blockbuster products like the cancer medicine Keytruda and wet macular product Eylea, which together generate approximately $25 billion in global sales," BGMA said. "The molecules coming off-patent also cover other disease areas including oncology, diabetes, arthritis, and asthma." While biological medicines dominate the medicines budget, constituting the largest cost and cost growth sectors, NHS England aims to expedite biosimilar availability, yielding substantial savings and expanding patient access to vital treatments. Yet, the report found that "this is jeopardised by the influence of the VPAS Scheme".

More than half of people (52%) do not feel confident in treating backache and less than half (44%) uses community pharmacists' advice as their first step on self-treatable conditions, a self-care attitudes 2022 survey has revealed. PAGB, the consumer healthcare association, surveyed over 2,000 adults across the UK about their attitudes towards self-care and access to health services. According to the survey, the public is in favour of self-care but many people lack the confidence and knowledge to care for the most common self-treatable conditions including backaches, headaches, diarrhoea and constipation. Four in five respondents (79%) said that people should take more responsibility for their own health and three-quarters (73%) believe that the NHS should make self-treatment easier. Behaviours around the current use of pharmacy varied - with less than half (44%) using community pharmacists as their first step in in getting advice on self-treatable conditions - but longer term attitudes were encouraging, with 69% supporting the idea of GPs being able to make referrals to pharmacists. Respondents also supported expanding the role of pharmacists so that their skills can be better utilised.

The British Generic Manufacturers Association (BGMA) has warned of the significant implications for future supply as a result of the crippling VPAS rate. The warning comes after the association's judicial review into the Government's decision to bar it from being a full part of the negotiations for the next five-year VPAS period was dismissed. The voluntary scheme for branded medicines pricing and access (VPAS) is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1%, but in 2023 it has soared to 26.5%. All biosimilars and a proportion of the generics market falls into the scheme.

Pharmaceutical Services Negotiating Committee has submitted its evidence to the House of Commons Health and Social Care Select Committee's recent inquiry into 'The future of General Practice'. The committee, chaired by former health secretary Jeremey Hunt MP, had launched an inquiry to explore the future of NHS GP over the next five years. PSNC's evidence focused on what community pharmacy is currently doing to support GPs, and what more can be done in the future. The negotiator said: "We focused on how pharmacies supported patients throughout the pandemic as the only primary care access point offering healthcare advice on a walk-in basis.

The Department of Health and Social Care (DHSC), NHS England and the Association of the British Pharmaceutical Industry (ABPI) have reached an agreement on the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The landmark deal will save the NHS £14 billion over 5 years in medicines costs, boost the nation's health, and support research investment. The new VPAG scheme, which will be a non-contractual voluntary agreement between DHSC and ABPI, will run for 5 years from 1 January 2024 until 31 December 2028. It will double the annual allowed growth of sales of branded medicines from two per cent per year in 2024 to four per cent per year by 2027.

The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS). The association had sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI) in April. Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: "For over 60 years the ABPI has acted as the representative industry body for negotiations on the Voluntary Scheme for branded medicines - a responsibility we take extremely seriously - and one which has been reaffirmed by today's judgment. "While we were disappointed that the BGMA decided to take this action - we recognise their decision was driven by the extreme challenge placed on all parts of the industry from the surge in the branded medicine payment rates. "The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in line with comparator countries to unlock investment and growth."

The British Generic Medicines Association (BGMA) has called for exemption from the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), an agreement between the UK Government, NHS England, and the pharmaceutical industry for branded generics and biosimilars. "Due to the rising rate of VPAS on top of existing competition, manufacturers are finding the additional levy economically unviable given their already low prices," the association said. According to research by the Office of Health Economics OHE and Professor Alistair McGuire (LSE) the rising rate of VPAS will force manufacturers pull out of the market which may lead to prices rise due to a lack of competition and critical savings to the NHS will be lost. The new study stated that Government levy on medicines designed to increase access to new treatments and promote affordability could actually be denying the NHS billions of pounds of annual savings due to the impact it is having on branded generics and biosimilars.

The British Generic Manufacturers Association (BGMA) has raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. The Department of Health Social Care (DHSC) today announced that the 2019 voluntary scheme payment percentage for 2023 will be 26.5%. The 2019 voluntary scheme for branded medicines pricing and access is an agreement between the Department of Health and Social Care, NHS England and the Association of the British Pharmaceutical Industry. BGMA believes that the high VPAS tax for 2023 risks more medicines shortages, rising prices for the NHS via reduced competition, and new medicine launches to the UK being deferred. Mark Samuels, Chief Executive of BGMA, said: "Raising the VPAS tax to 26.5% will damage the UK's medicines supply because it will make some products lossmaking. It is more than a five-fold tax increase from 2021, and no industry can cope with this unpredictable and exceptional tax volatility.

NHS Somerset is aiming to grow its referral rate through GP Community Pharmacist Consultation Service (GP CPCS) to between 4,000 to 6,000 patients a month. Since June 2021 GPs in Somerset have successfully referred around 1,000 patients a month through the Somerset GP Community Pharmacist Consultation Service (GP CPCS) Currently, 59 of NHS Somerset's 64 GP practices and all of Somerset's 102 community pharmacists are using the Somerset GP CPCS. NHS Somerset found that providing the right training for GPs and for reception staff and practice managers was key to a smooth rollout and uptake of the service. As was making sure the technology worked when making referrals from general practice to community pharmacists. NHS Somerset is using software called Patient Access Connect, which seamlessly integrates with the EMIS Web GP system used in Somerset, to give practices a quick and easy way to capture the patient information needed to deliver a referral.

In a groundbreaking move towards modernising healthcare, England's National Health Service (NHS) has successfully implemented digital prescriptions, as reported by the World Health Organization (WHO) in its latest regional digital health report. Since January 2024, patients across England have had access to their prescription information through the NHS App, marking a significant leap in healthcare accessibility and efficiency. With over 33 million registered users, representing 75 per cent of the adult population, the NHS App has become a vital tool in managing healthcare online. The introduction of digital prescriptions allows users to order repeat prescriptions online without the need for a GP visit. This innovation has witnessed a surge in digital requests, with over 3.1 million repeat prescriptions processed monthly.